The IDEAL study comparing simvastatin 20-40 mg versus atorvastatin 80 mg for secondary prevention after myocardial infarction: Between two ideas of the ideal;L'étude clinique du mois: L'étude IDEAL comparant simvastatine 20-40 mg versus atorvastatine 80 mg en prévention après un infarctus du myocarde: Entre deux idées de l'idéal

Revue Medicale de Liege

Volumn 61, Issue 1, 2006, Pages 53-59

  Scheen, A J ^a,b,c  

^a UNIVERSITY OF LIÈGE   (Belgium)

^b Service de Diabétologie Nutrition et Maladies Métaboliques   (Belgium)

^c UNIVERSITY OF LIÈGE   (Belgium)

Author keywords

Atorvastatin; Cholesterol; Coronary heart disease; Myocardial infarction; Secondary prevention; Simvastatin

Indexed keywords

ATORVASTATIN; SIMVASTATIN; HEPTANOIC ACID DERIVATIVE; HYPOCHOLESTEROLEMIC AGENT; LOW DENSITY LIPOPROTEIN CHOLESTEROL; PYRROLE DERIVATIVE;

ACUTE HEART INFARCTION; ADULT; AGED; CHOLESTEROL BLOOD LEVEL; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CORONARY ARTERY DISEASE; DRUG MEGADOSE; FEMALE; FOLLOW UP; HEART ARREST; HEART INFARCTION; HUMAN; ISCHEMIC HEART DISEASE; MAJOR CLINICAL STUDY; MALE; MORTALITY; PROSPECTIVE STUDY; RANDOMIZED CONTROLLED TRIAL; REVIEW; SECONDARY PREVENTION; TREATMENT OUTCOME; ARTICLE; BLOOD; CARDIOVASCULAR DISEASE; DRUG EFFECT; MIDDLE AGED; MULTICENTER STUDY; RISK FACTOR; SINGLE BLIND PROCEDURE;

ANTICHOLESTEREMIC AGENTS; CARDIOVASCULAR DISEASES; CHOLESTEROL, LDL; FEMALE; HEPTANOIC ACIDS; HUMANS; MALE; MIDDLE AGED; MYOCARDIAL INFARCTION; PROSPECTIVE STUDIES; PYRROLES; RISK FACTORS; SIMVASTATIN; SINGLE-BLIND METHOD; TREATMENT OUTCOME;

EID: 32244437821     PISSN: 00353663     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (21)

1. Scheen AJ.- Le risque cardio-vasculaire lié à l'hypercholestérolémie: d'un continuum à la notion de normalité, de seuil d'intervention et d'objectif thérapeutique. Rev Med Liège, 1999, 54, 17-21.
2. Law MR, Wald NJ, Rudnicka AR.- Quantifying effect of statins on low density lipoprotein cholesterol, ischaemic heart disease, and stroke: systematic review and meta-analysis. BMJ, 2003, 326, 1423-1427.
3. Baigent C, Keech A, Kearney PM, et al.- Efficacy and safety of cholesterol-lowering treatment: prospective meta-analysis of data from 90,056 participants in 14 randomised trials of statins. Lancet, 2005, 366, 1267-1278.
4. Pitt B.- Low-density lipoprotein cholesterol in patients with stable coronary heart disease: is it time to shift our goals? (Editorial). N Engl J Med, 2005, 352, 1483-1484.
5. Scheen AJ, Kulbertus H.- "REVERSAL" et "PROVE-IT": confirmation du concept «the lower, the better» dans le traitement de l'hypercholestérolémie chez le patient coronarien. Rev Med Liège, 2004, 59, 167-173.
6. LaRosa JC, Grundy SM, Waters DD, et al.- Intensive lipid lowering with atorvastatin in patients with stable coronary disease. N Engl J Med, 2005, 352, 1425-1435.
7. Scandinavian Simvastatin Survival Study Group.- Randomised trial of cholesterol lowering in 4444 patients with coronary heart disease: the Scandinavian Simvastatin Survival Study (4S). Lancet, 1994, 344, 1383-1389.
8. Heart Protection Study Collaborative Group.- MRC/BHF Heart Protection Study of cholesterol lowering with simvastatin in 20,536 high risk individuals. Lancet, 2002, 360, 7-22.
9. Pedersen TR, Faergeman O, Kastelein JJP et al. for the Increment Decrease in End Points Through Aggressive Lipid Lowering (IDEAL) Study Group.- High-dose atorvastatin vs usual-dose Simvastatin for secondary prevention after myocardial infarction. The IDEAL study: a randomized controlled trial. JAMA, 2005, 294, 2437-2445.
10. Scheen AJ.- Comment j'explore... les critères de jugement dans les essais cliniques: réflexion à propos d'études récentes de prévention cardio-vasculaire. Rev Med Liège, 2006, 61, soumis pour publication.
11. Cannon CP.- The IDEAL cholesterol. Lower is better (Editorial). JAMA, 2005, 294, 2492-2494.
12. Cannon CP, Braunwald E, McCabe CH, et al.- Comparison of intensive and moderate lipid lowering with statins after acute coronary syndromes. N Engl J Med, 2004, 350, 1495-1504.
13. de Lemos JA, Blazing MA, Wiviott SD, et al.- Early intensive vs a delayed conservative simvastatin strategy in patients with acute coronary syndromes: phase Z of the A to Z trial. JAMA, 2004, 292, 1307-1316.
14. Koren MJ, Hunninghake DB.- Clinical outcomes in managed-care patients with coronary heart disease treated aggressively in lipid-lowering disease management clinics: the ALLIANCE study. J Am Coll Cordial, 2004, 44, 1772-1779.
15. Scheen AJ.- Treating to New Targets: plaidoyer pour une valeur cible de cholestérol LDL égale ou inférieure à 75 mg/dl chez tout patient coronarien. Rev Med Liège, 2005, 60, 264-267.
16. Bonetti PO, Lerman LO, Napoli C, Lerman A.- Statin effects beyond lipid lowering - are they clinically relevant? Eur Heart J, 2003, 24, 225-248.
17. Scheen AJ, Kulbertus H.- Prévention cardio-vasculaire par les statines: faut-il encore doser le cholestérol? Rev Med Liège, 2003, 58, 191-197.
18. Scheen AJ.- Pharmaco-économie des médicaments hypolipidémiants: analyse des facteurs influencant le rapport coût/efficacité. Rev Med Liège, 1998, 53, 220-222.
19. Van den Bruel A, Gobert M, Vermeire E, et al.- Traitement pharmacologique de l'hypercholestérolémie en prévention primaire. L'exploitation des sources d'information. Rev Med Liège, 2005, 60, 711-718.
20. Scheen AJ.- Comment j'explore... Le risque cardiovasculaire absolu à 10 ans: de Framingham 1998 à SCORE 2003. Rev Med Liège, 2004, 59, 460-466.
21. Scheen AJ, Lefèbvre PJ, Kulbertus H.- Comment je préviens... Les maladies cardio-vasculaires par une approche pharmacologique combinée: y a-t-il place pour une «polypill»? Rev Med Liège, 2003, 58, 527-533.